Close Menu

OpGen

The company's full-year revenues were $4.2 million, up 20 percent from the year-ago quarter.

News items for the in vitro diagnostics industry for the week of March 8, 2021.

The company's cartridge for pneumonia for the Unyvero system is under review and pending approval by Chinese regulators.

A single healthcare-focused investor will purchase 2.78 million shares of common stock, 5.55 million prefunded warrants, and an additional 4.17 million shares of common stock.

Despite the Q4 revenue increase, sales for FY2020 dropped 13 percent year over year to $5.2 million.

News items for the in vitro diagnostics industry for the week of Jan. 4, 2021.

Under the terms of the agreement, OpGen would sell $10 million in stock and warrants to a US-based healthcare-focused institutional investor.

The firm beat the consensus Wall Street estimate on the top line but fell short of the estimate on the bottom line.

News items for the in vitro diagnostics industry for the week of Oct. 26, 2020.

Pages